Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
Insmed, Inc. (Symbol: INSM) is a global biopharmaceutical company headquartered in Bridgewater, NJ, with a mission to transform the lives of patients with serious and rare diseases. The company is committed to developing and bringing to market therapies that significantly improve patient lives, focusing on the entire patient journey from diagnosis and treatment to daily living.
Insmed's flagship product, ARIKAYCE (amikacin liposome inhalation suspension), is approved in the US for treating Mycobacterium Avium Complex (MAC) lung disease in adult patients who have limited or no alternative treatment options. ARIKAYCE, utilizing Insmed's proprietary PULMOVANCE® liposomal technology, delivers amikacin directly to the lungs, reducing systemic exposure and associated toxicities. It is administered using the Lamira® Nebulizer System developed by PARI Pharma GmbH, known for its efficiency and portability.
The company’s clinical pipeline includes multiple promising candidates. Notable among them is Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 (DPP1). It is being developed for treating non-cystic fibrosis bronchiectasis and other neutrophil-mediated diseases. Another significant pipeline product is TPIP (Treprostinil Palmitil Inhalation Powder), an inhaled formulation being evaluated for pulmonary arterial hypertension and other serious pulmonary disorders.
Insmed has demonstrated robust financial performance, with significant revenue growth driven by ARIKAYCE. The company continues to invest heavily in research and development, with plans to expand its product portfolio and market reach globally.
Insmed's strategic partnerships and collaborations play a crucial role in advancing its mission. These include collaborations with PARI Pharma for the Lamira® Nebulizer System and AstraZeneca AB for utilizing their expertise in respiratory diseases.
Recent updates include positive financial results for the third quarter of 2023, robust revenue growth from ARIKAYCE, and significant progress in clinical trials. Noteworthy are the topline results from the Phase 3 ASPEN study for Brensocatib, indicating its potential as a first-in-class treatment. Insmed plans to file a New Drug Application (NDA) with the FDA for Brensocatib by late 2024, aiming for a potential launch in 2025.
The company is also advancing its early-stage research engine, exploring innovative technologies such as artificial intelligence-driven protein engineering and gene therapy, positioning itself at the forefront of biopharmaceutical innovation.
Insmed (INSM) has granted inducement awards to 30 new employees as part of their employment agreements. The awards consist of options to purchase a total of 64,240 shares of Insmed common stock at an exercise price of $72.42 per share, which was the closing price on the Nasdaq Global Select Market on the grant date of December 2, 2024.
The stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after the first year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment with Insmed.
Insmed (Nasdaq: INSM) has announced its participation in two major investor conferences in December 2024. The company will present at the Evercore ISI HealthCONx Conference in Coral Gables, Florida, on December 4 at 11:15 a.m. ET, and at the Nasdaq 51st Investor Conference in London on December 11 at 10:30 a.m. GT (5:30 a.m. ET). Both presentations will be available via webcast on the company's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM) has granted inducement awards to 27 new employees as of November 1, 2024. The awards consist of options to purchase a total of 66,740 shares of common stock at an exercise price of $68.32 per share, which was the closing price on Nasdaq Global Select Market on the grant date. These stock options have a 10-year term and follow a four-year vesting schedule: 25% vests after one year, followed by 12.5% vesting every six months until the fourth anniversary, contingent on continued employment.
Insmed (Nasdaq: INSM) has announced its participation in four major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference in Boston (Nov. 11), UBS Global Healthcare Conference in Rancho Palos Verdes (Nov. 12), Wolfe Research Healthcare Conference in New York (Nov. 20), and Jefferies London Healthcare Conference in London (Nov. 21). All presentations will be webcast live through Insmed's investor relations website and archived for 30 days after the events.
Insmed (INSM) reported Q3 2024 financial results with ARIKAYCE revenue of $93.4 million, showing 18% growth year-over-year. The company maintained its 2024 global ARIKAYCE revenue guidance of $340-360 million. The quarter ended with approximately $1.5 billion in cash and equivalents. Key developments include the planned NDA submission for Brensocatib in Q4 2024 with potential U.S. launch in mid-2025, and a renegotiated term loan providing an additional $150 million. The company reported a net loss of $220.5 million ($1.27 per share) compared to $158.9 million ($1.11 per share) in Q3 2023.
Insmed (Nasdaq:INSM) has secured the #1 position in Science's 2024 Top Employers Survey for the fourth consecutive year. The survey, which gathered nearly 6,500 responses primarily from North America (65%), Europe (19%), and Asia/Pacific Rim (11%), evaluates companies in biotechnology and pharmaceutical industries.
The company stood out for its innovative leadership, respect for employees, social responsibility, and employee loyalty. With over 1,200 employees worldwide, Insmed has demonstrated strength in commercial and pipeline programs while maintaining its commitment to transforming patients' lives with serious diseases. The recognition highlights Insmed's distinctive culture and continued global expansion.
Insmed (INSM) held its third annual Global Day of Good, involving over 1,000 employees in volunteer activities across the U.S., Europe, and Japan. The company-wide service day supported more than 40 organizations globally, focusing on improving health, education, and human services. Activities included preparing kits for pediatric cancer patients, building playhouses, revitalizing community centers, packing food for pantries, sorting clothing donations, and translating children's books. Both remote and in-person volunteering options were available to ensure all employees could participate.
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company, has announced that it will release its third-quarter 2024 financial results on Thursday, October 31, 2024. The company will host a conference call for investors at 8:00 a.m. ET on the same day to discuss the financial results and provide a business update.
Shareholders and interested parties can participate in the conference call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) and using the access code 7862189. The call will also be webcast live on Insmed's website. A replay of the call will be available until November 7, 2024, and a webcast will be archived for 90 days on the company's website.
Insmed Incorporated (Nasdaq: INSM) presented positive late-breaking subgroup data from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis at the CHEST 2024 Annual Meeting. The subgroup analyses showed consistent positive impact on the rate of exacerbations across most prespecified subgroups, aligning with the overall trial results. Notably, brensocatib 25 mg demonstrated a reduced decline in lung function (FEV1) at Week 52 versus placebo for all prespecified subgroups.
The drug was well-tolerated, with common adverse events including COVID-19, nasopharyngitis, cough, and headache. Insmed plans to file a New Drug Application with the FDA in Q4 2024, aiming for a U.S. launch in mid-2025 and European and Japanese launches in H1 2026. If approved, brensocatib would be the first approved treatment for bronchiectasis and the first approved DPP1 inhibitor.
Insmed Incorporated (Nasdaq: INSM) has announced the granting of inducement awards to 52 new employees in accordance with NASDAQ Listing Rule 5635(c)(4). The awards, approved by Insmed's Compensation Committee, were made as a material inducement to each employee's entry into employment with the Company.
On October 1, 2024, the new employees received options to purchase an aggregate of 106,160 shares of Insmed common stock at an exercise price of $72.88 per share, which was the closing trading price on the Nasdaq Global Select Market on the date of grant. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and 12.5% vesting every six months thereafter through the fourth anniversary, subject to continued service with Insmed.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
What is Insmed's primary mission?
What is ARIKAYCE?
What are Brensocatib and TPIP?
Where is Insmed headquartered?
What are Insmed's recent financial highlights?
What are the strategic partnerships of Insmed?
What are the latest developments in Insmed's clinical trials?
What is Insmed's approach to early-stage research?
What is the Lamira® Nebulizer System?
When does Insmed plan to file an NDA for Brensocatib?
